CRISPR Therapeutics AG (NASDAQ:CRSP) is among the 12 Best Genomics Stocks to Invest In.
TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG while reducing its price target from $82 to $74. The firm stated that the modification came after revisions to its business model following the third-quarter report.
Besides that, it was reported on December 22, 2025, that CRISPR Therapeutics AG offered clinical updates on zugocaptagene geleucel. It is also known as zugo-cel (previously CTX112), an experimental allogeneic CAR T treatment that targets CD19 for hematologic malignancies and autoimmune diseases. A Phase 1 basket trial for autoimmune rheumatologic disorders is now evaluating Zugo-cel. Four patients treated with a 100 million cell dose and monitored for at least 28 days exhibited cell expansion similar to that observed at the same dose in B-cell lymphoma trials as of the December 17, 2025, data cut-off. B-cell depletion was seen to occur quickly and persistently in one to two days. On Day 28, all patients had considerable clinical improvement. A patient with systemic lupus erythematosus who was unresponsive to nine previous treatments continued to experience drug-free DORIS clinical remission through the sixth month of treatment.
As of November 20, 2025, ten patients with refractory or relapsed large B-cell lymphoma were receiving treatment at the recommended Phase 2 dose of 600 million cells for hematologic malignancies. There were reports of a 90% overall response rate and a 70% full response rate. After 12 months of follow-up, 67% of patients were in full response.
CRISPR Therapeutics AG is a gene editing firm that focuses on the development of CRISPR/Cas9-based therapies.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None
